
Lyra Therapeutics (LYRA) P/E Ratio
P/E Ratio as of Jun 13, 2025: -0.19
Average-0.1924
Median-0.0900
Minimum-0.4500
Maximum-0.0700
-0.19
Past Month-0.10 (111.11%)
The P/E ratio for Lyra Therapeutics (LYRA) is -0.19 as of Jun 13, 2025. This represents a increase of 18.75% compared to its 12-month average P/E ratio of -0.16. A higher P/E ratio suggests that investors expect strong future earnings growth, while a lower P/E ratio may indicate a potentially undervalued stock or slowing growth.
Lyra Therapeutics P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)
Lyra Therapeutics’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing Lyra Therapeutics to industry peers.
Lyra Therapeutics P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)
Lyra Therapeutics’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing Lyra Therapeutics to industry peers.
Lyra Therapeutics (LYRA) P/E Ratio Insights
See Lyra Therapeutics’s latest P/E ratio, historical trends, and valuation insights with AI-powered fundamental data and custom analysis.
Start investing in Lyra Therapeutics (LYRA)
Order type
Buy in
Order amount
Est. shares
0 shares
Lyra Therapeutics (LYRA) P/E Ratio Historic Data
Date | Stock price | P/E ratio |
---|---|---|
Jun 2, 2025 | $20.25 | -0.33 |
May 1, 2025 | $5.575 | -0.09 |
Apr 1, 2025 | $6.005 | -0.10 |
Mar 3, 2025 | $9.72 | -0.14 |
Feb 3, 2025 | $9.115 | -0.13 |
Jan 2, 2025 | $10.80 | -0.15 |
Lyra Therapeutics (LYRA) End of Year P/E Ratio
Date | P/E ratio | Change |
---|---|---|
2025 | -0.19 | +35.71% |
2024 | -0.14 | -95.94% |
2023 | -3.45 | +205.31% |
2022 | -1.13 | -13.08% |
2021 | -1.30 | -80.39% |
2020 | -6.63 | — |
FAQs About Lyra Therapeutics (LYRA) P/E ratio
The latest P/E ratio of Lyra Therapeutics (LYRA) is -0.19, as of Jun 13, 2025. This is calculated based on its current stock price and earnings per share (EPS).
Lyra Therapeutics’s last 12-month average P/E ratio is -0.16, compared to its current P/E ratio of -0.19. This reflects a increase of 18.75%.
Lyra Therapeutics’s current P/E ratio of -0.19 is higher than its last 12-month average P/E of -0.16. A higher P/E can indicate strong future growth expectations, while a lower P/E might suggest undervaluation.
Lyra Therapeutics’s average P/E ratio over the last 3 years is -1.53. Comparing this to the current P/E helps assess recent valuation trends and whether the stock is trading above or below its mid-term historical range.
Lyra Therapeutics’s average P/E ratio over the last 5 years is -2.05. A deviation from this historical average may indicate shifts in growth expectations, profitability, or broader market conditions affecting valuation.